Výsledky vyhledávání - "Sally Naji Temraz"

Quality-of-life outcomes after total neoadjuvant short course radiotherapy, chemo-immunotherapy, and total mesorectal excision for locally advanced rectal cancer

Autor: Ali Shamseddine, Laudy Chehade, Joseph Gergi Kattan, Sally Naji Temraz, Rula Amarin, Tala Awabdeh, Maya Charafeddine, Monita Al Darazi, Rim Turfa

Publikováno v: Journal of Clinical Oncology. 41:63-63

63 Background: A growing body of evidence supports total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC), however the optimal regimen is yet to be determined and little is known on the quality-of-life (QOL) implications of these t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3fa8b5dd5bbfc4a4f62b5a1b3293868
https://doi.org/10.1200/jco.2023.41.4_suppl.63

Zobrazit plný text záznamu

Assessment of immunoscore and MRI tumor regression grade to predict complete pathologic response in patients with locally advanced rectal cancer: Data from phase II Averectal study

Autor: Ali Shamseddine, Ahmad Machmouchi, Mustafa Natout, Rim Turfa, Joseph Gergi Kattan, Sally Naji Temraz, Ayman Tawil, Mousa Elkhaldi, Omar Jaber, Rula Amarin, Tala Awabdeh, Maya Charafeddine, Monita Al Darazi, Hero Hussain

Publikováno v: Journal of Clinical Oncology. 41:212-212

212 Background: In patients with locally advanced rectal cancer (LARC), magnetic resonance imaging is the most accurate non-invasive staging tool, enabling response assessment to total neoadjuvant therapy. Wang et al had reported that 46.6% of patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0f144de75744e669aafb0724bedc9d6b
https://doi.org/10.1200/jco.2023.41.4_suppl.212

Zobrazit plný text záznamu

High immunoscore as a predictor of outcome in patients who underwent chemoimmuno-therapy in locally advanced rectal cancer: A post-hoc analysis of the correlation between immunoscore and pCR in the Averectal study

Publikováno v: Journal of Clinical Oncology. 40:184-184

184 Background: The immunoscore (IS), a prognostic score, was first validated in early colon cancer reflecting the immune response against the tumor. It showed potential in its ability to downstage patients with pathologic complete response (pCR) who

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bd7643c9f62b88dfeb9a7243ba6ee286
https://doi.org/10.1200/jco.2022.40.4_suppl.184

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání